[HTML][HTML] High-strength opioid formulations: the case for a ministerial recall

M Herder, D Juurlink - CMAJ, 2018 - Can Med Assoc
CMAJ| DECEMBER 3, 2018| VOLUME 190| ISSUE 48 E1405 formulations covered under
our proposal, which were approved for the treatment of chronic pain, yield about 200 to 400 …

[HTML][HTML] Is there support for abuse-deterrent and tamper-resistant opioid formulations?

RN Jamison - The Journal of Pain, 2013 - jpain.org
Recent attention has been given to the development of abuse-deterrent and tamper-
resistant opioid formulations in light of concern over the epidemic misuse of opioids …

FDA tightens indications for using long-acting and extended-release opioids to treat chronic pain

BM Kuehn - Jama, 2013 - jamanetwork.com
In an effort to help curb the ongoing epidemic of prescription opioid abuse and overdoses,
the US Food and Drug Administration (FDA) is tightening the indications for long-acting and …

[PDF][PDF] Confronting the opioid crisis by taking a long look in the mirror… and at our peers

GP Hays, MB Mycyk - 2018 - scholarworks.iupui.edu
National attention to our current opioid epidemic continues to increase at a numbing pace.
According to the latest estimates from the Centers for Disease Control and Prevention …

Suggested paths to fixing the opioid crisis: directions and misdirections

JH Samet, SG Kertesz - JAMA network open, 2018 - jamanetwork.com
The opioid crisis and its morbid and mortal consequences have captured the public
spotlight, and rightly so. In response, public health professionals have pursued a variety of …

[HTML][HTML] Inconsistencies in the 2017 Canadian guideline for opioids for chronic noncancer pain

EL Weinberg, PA Baer - CMAJ, 2017 - Can Med Assoc
With the 2017 Canadian Guideline for Opioids for Chronic Noncancer Pain (the guideline)
currently undergoing an independent assessment of the rigour that went into its …

[HTML][HTML] Opioids for chronic pain

M Ross - CMAJ, 2018 - Can Med Assoc
Some patients with chronic pain are suf fering from considerable anxiety and increased pain
because their doctors are lowering their use of opioids against their will (www. cbc …

[HTML][HTML] Legislative Initiatives and Review of Abuse-Deterrent Opioid Formulations

P LAW - US Pharm, 2013 - uspharmacist.com
Opioid analgesics are the mainstay treatment of moderate-to-severe pain. However, opioids
carry a risk of misuse, abuse, and death, and recently have become a public health …

[PDF][PDF] Opioid dosing policy: Pharmacological considerations regarding equianalgesic dosing

J Fudin, M Raouf, EL Wegrzyn - American Academy of Integrative Pain …, 2017 - rsds.org
As the United States grapples with the public health crisis of opioid misuse, abuse,
addiction, and overdose deaths, one common response from policymakers and third-party …

Impact of delisting high‐strength opioid formulations from a public drug benefit formulary on opioid utilization in Ontario, Canada

D Martins, W Khuu, M Tadrous… - … and Drug Safety, 2019 - Wiley Online Library
Purpose High‐strength opioid formulations were delisted (removed) from Ontario's public
drug formulary in January 2017, except for palliative patients. We evaluated the impact of …